Discrepancies between Preoperative and Postoperative Histology following Robot Assisted Radical Cystectomy

Results from the International Robotic Cystectomy Consortium

  • Ali Ahmad Roswell Park Cancer Institute
  • Ayat A. Shah
  • Zhe Jing
  • Philippa Doherty
  • Andrew A. Wagner
  • Jihad Kaouk
  • Michael Stöckle
  • Eric Kim
  • Prokar Dasgupta
  • Franco Gaboardi
  • Carl Wijburg
  • Ashok Hemal
  • Derya Balbay
  • Ahmed Aboumohamed
  • Lee Richstone
  • Thomas J. Maatman
  • Koon Ho Rha
  • Peter Wiklund
  • Ahmed A. Hussein
  • Khurshid A. Guru

Abstract

Introduction and Objective: We aimed to investigate the discrepancy between preoperative and postoperative histology in terms of the presence of variant histology (VH) following Robot-Assisted Radical Cystectomy (RARC) and its impact on oncologic outcomes.

Methods: A retrospective review of the multi-institutional prospectively maintained database, the International Robotic Cystectomy Consortium (IRCC), was performed. Preoperative histology was compared with the histology at RARC to determine discrepancies in terms of the presence of VH. Descriptive statistics were used to summarize the data. Multivariate analysis (MVA) was performed to identify variables associated with a discrepancy in histology. The Kaplan Meier method was used to depict recurrence-free (RFS), disease-specific (DSS), and overall survival (OS).

Results: Mean age was 69 years and 20% of patients received neoadjuvant chemotherapy (NAC). 25% exhibited a discrepancy between preoperative and postoperative histology; 17% had pure urothelial (PU) preoperatively and were found to have VH at RARC, and 8% had VH preoperatively that was no longer evident at RARC. There was no significant difference between those who exhibited discrepancy versus those who did not in terms of pT, pN, surgical margins, or recurrences (p>0.05 for all). There was a significant difference in RFS and DSS (log rank 0.01 and <0.01, respectively). Patients with PU histology at RARC (pre/post PU and pre VH/post PU) exhibited better OS compared to those with VH at RARC (pre/post VH and pre PU/post VH) (log rank p<0.01). Patients with higher preoperative grade (OR: 4.19; 95% CI: 1.3-13.7; p<0.01) and with preoperative nodal involvement (OR: 2.29, 95% CI: 1.2-4.3; p=0.01) were more likely to have different histology postoperatively.

Conclusion: Discrepancies between preoperative and postoperative histology occurred in 25% of patients after RARC. Patients with preoperative variant histology that was no longer evident on postop histology exhibited similar survival to those with purely urothelial histology.

##plugins.generic.usageStats.downloads##

##plugins.generic.usageStats.noStats##

Riferimenti bibliografici

1. Stroman, L., et al., The impact of non-urothelial variant histology on oncological outcomes following radical cystectomy. BJU Int, 2019. 124(3): p. 418-423.
2. Sefik, E., et al., Effect of variant histology presence and squamous differentiation on oncological results and patient's survival after radical cystectomy. Arch Ital Urol Androl, 2018. 90(3): p. 172-175.
3. Black, P.C., G.A. Brown, and C.P. Dinney. The impact of variant histology on the outcome of bladder cancer treated with curative intent. in Urologic Oncology: Seminars and Original Investigations. 2009. Elsevier.
4. Willis, D.L., et al. Micropapillary bladder cancer: current treatment patterns and review of the literature. in Urologic Oncology: Seminars and Original Investigations. 2014. Elsevier.
5. Gordetsky, J., et al., Second Opinion Expert Pathology Review in Bladder Cancer: Implications for Patient Care. Int J Surg Pathol, 2018. 26(1): p. 12-17.
6. Lobo, N., et al., What Is the Significance of Variant Histology in Urothelial Carcinoma? Eur Urol Focus, 2020. 6(4): p. 653-663.
7. Kaimakliotis, H.Z., et al., Plasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes. Urology, 2014. 83(5): p. 1112-1116.
8. Warrick, J.I., Clinical significance of histologic variants of bladder cancer. Journal of the National Comprehensive Cancer Network, 2017. 15(10): p. 1268-1274.
9. Gerlinger, M., et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl j Med, 2012. 366: p. 883-892.
10. Meeks, J.J., et al., Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature Reviews Urology, 2020. 17(5): p. 259-270.
11. Black, P., Should Variant Histology Change Management of Bladder Cancer. Grand Rounds in Urology, 2018.
12. Daneshmand, S. and A. Nazemi, Neoadjuvant chemotherapy in variant histology bladder cancer: current evidence. European Urology Focus, 2020. 6(4): p. 639-641.
13. da Costa, J.B., et al. Molecular tumor heterogeneity in muscle invasive bladder cancer: biomarkers, subtypes, and implications for therapy. in Urologic Oncology: Seminars and Original Investigations. 2018. Elsevier.
14. Abd el-Latif, A., et al., The sensitivity of initial transurethral resection or biopsy of bladder tumor (s) for detecting bladder cancer variants on radical cystectomy. The Journal of urology, 2013. 189(4): p. 1263-1267.
15. Philip, A.T., et al., Intravesical adipose tissue: a quantitative study of its presence and location with implications for therapy and prognosis. Am J Surg Pathol, 2000. 24(9): p. 1286-90.
16. Hansel, D.E., et al., A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. European urology, 2013. 63(2): p. 321-332.
17. Moschini, M., et al., Characteristics and clinical significance of histological variants of bladder cancer. Nature Reviews Urology, 2017. 14(11): p. 651-668.
Pubblicato
2023-09-28
##submission.howToCite##
Sezione
Original Articles

##plugins.generic.recommendByAuthor.heading##